Sinovac Phase 3 Trial Results Expected Next Week

"); jQuery("#212 h3").html("

Related News Programmes

"); jQuery(document).ready(function() { jwplayer.key='EKOtdBrvhiKxeOU807UIF56TaHWapYjKnFiG7ipl3gw='; var playerInstance = jwplayer("jquery_jwplayer_1"); playerInstance.setup({ file: "https://newsstatic.rthk.hk/audios/mfile_1565715_1_20201217054113.mp3", skin: { url: location.href.split('/', 4).join('/') + '/jwplayer/skin/rthk/five.css', name: 'five' }, hlshtml: true, width: "100%", height: 30, wmode: 'transparent', primary: navigator.userAgent.indexOf("Trident")>-1 ? "flash" : "html5", events: { onPlay: function(event) { dcsMultiTrack('DCS.dcsuri', 'https://news.rthk.hk/rthk/en/component/k2/1565715-20201217.mp3', 'WT.ti', ' Audio at newsfeed', 'WT.cg_n', '#rthknews', 'WT.cg_s', 'Multimedia','WT.es','https://news.rthk.hk/rthk/en/component/k2/1565715-20201217.htm', 'DCS.dcsqry', '' ); } } }); }); });

2020-12-17 HKT 05:38

Share this story

facebook

  • The government announced last week that it has secured 7.5 million doses from the mainland firm. Photo: Shutterstock

    The government announced last week that it has secured 7.5 million doses from the mainland firm. Photo: Shutterstock

Government adviser and respiratory medicine expert Dr David Hui said on Wednesday that he expected the phase 3 clinical trial results of the Sinovac coronavirus vaccine to be out on December 23.

The government announced last week that it had secured 7.5 million doses from the mainland firm as part of its procurement programme.

Dr Hui said if there were no problems with the trial results, the vaccine could be introduced here next month.

"At the moment Sinovac has published phase 1 and phase 2 data, showing the antibodies can develop in over 90 percent of the recipients," he said.

Dr Hui said that only when the company had good data would the vaccine be introduced in Hong Kong.

The government is making arrangements for three vaccines: Sinovac, Fosun BioNTech and Astrazeneca.

Dr Hui said the public wouldn't get to choose which vaccine they would get because this could lead to a shortage of one type of vaccine and a surplus of another.

He said any vaccine that was in surplus might therefore end up being wasted, as they have a shelf-life of about six months.

RECENT NEWS

ZA Bank Brings Nasdaq Data To Hong Kong, Expanding US Stock Access And Investor Education

ZA Bank and Nasdaq have announced a collaboration aimed at enhancing digital wealth management in Hong Kong and interna... Read more

Hong Kong To Study One‑Stop Infrastructure For Equities, Bonds And Digital Assets

The Hong Kong Monetary Authority’s (HKMA) CMU OmniClear and the Hong Kong Exchange (HKEX) are set to begin a study on... Read more

Hong Kong To Issue First Stablecoin Licenses In March, Expand Crypto Regulation

Hong Kong will issue its first licenses for fiat-referenced stablecoin issuers in March and introduce new legislation l... Read more

MSIG Joins US$6B IFC Credit Insurance Facility To Boost Emerging Market Lending

MSIG USA and Mitsui Sumitomo Insurance (MSI Japan), together referred to as MSIG, have joined a new insurance-ba... Read more

Why The $2 Trillion Stablecoin Prediction Is Too Low

McKinsey estimates the stablecoin market will hit $2 trillion by 2028. But according to Sam Lin, COO of dtcpay, even th... Read more

RedotPay Eyes US IPO With Potential US$1 Billion Raise

RedotPay is reportedly exploring an IPO in the US that could raise more than US$1 billion, according to people famili... Read more